Health ❯ Healthcare ❯ Medical Research ❯ Cancer Research

Pancreatic Cancer

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Published in the New England Journal of Medicine after an ASCO presentation, regulators have authorised expanded access for daraxonrasib pending formal review.

4 ARTICLES

last mo.

NADPH Disruption Fuels Early Pancreatic Lesions as ME1 Loss Drives Cancer Progression

3 ARTICLES

5mo ago

NIH-Supported Study Unveils Four-Marker Blood Test for Earlier Detection of Pancreatic Cancer

16 ARTICLES

5mo ago

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

3 ARTICLES

5mo ago

Low CTDNEP1 Tied to Poorer Outcomes in Pancreatic Cancer, Study Finds

13 ARTICLES

9mo ago

27 Oral Microbes Tied to 3.5-Fold Higher Pancreatic Cancer Risk in Large Saliva Study

3 ARTICLES

10mo ago

KRAS-Targeted Vaccine Shows Robust Immune Response, Longer-Than-Expected Survival in Pancreatic and Colorectal Cancer Trial

17 ARTICLES

10mo ago

Off-The-Shelf KRAS Vaccine Yields Robust T-Cell Responses and Survival Benefit

Pancreatic Cancer

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Low‑Risk Pancreatic Cysts Linked to Much Higher Long‑Term Cancer Risk

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

Mayo Clinic AI Flags Pancreatic Cancer on CT Scans Up to Three Years Early

NADPH Disruption Fuels Early Pancreatic Lesions as ME1 Loss Drives Cancer Progression

NIH-Supported Study Unveils Four-Marker Blood Test for Earlier Detection of Pancreatic Cancer

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Low CTDNEP1 Tied to Poorer Outcomes in Pancreatic Cancer, Study Finds

27 Oral Microbes Tied to 3.5-Fold Higher Pancreatic Cancer Risk in Large Saliva Study

KRAS-Targeted Vaccine Shows Robust Immune Response, Longer-Than-Expected Survival in Pancreatic and Colorectal Cancer Trial

Off-The-Shelf KRAS Vaccine Yields Robust T-Cell Responses and Survival Benefit